The 31st Congress of the European Hematology Association (EHA 2026) is taking place from June 11–14, 2026, in Stockholm, Sweden. As one of the world's leading scientific meetings in hematology, EHA brings together hematologists, clinicians, researchers, and industry experts from around the globe to discuss the latest advances in basic research, clinical practice, translational medicine, and innovative therapies for hematologic diseases.

Driven by an unwavering commitment to improving patient outcomes, GoBroad Healthcare Group physicians continue to integrate clinical practice with scientific research, addressing unmet needs in hematologic malignancies and blood disorders. At EHA 2026, the GoBroad physician team presents 27 scientific contributions spanning cellular immunotherapy, hematopoietic stem cell transplantation, treatment strategies for relapsed/refractory hematologic malignancies, disease biology, precision classification, and prognostic assessment.

These studies highlight GoBroad’s ongoing efforts in clinical innovation, translational research, and multidisciplinary collaboration, while showcasing valuable insights and real-world experience from China’s hematology community on the global academic stage.

Oral Presentation

Abstract No. S330

Title: First-in-Human Study of Alpaca-Derived Nanobody-Based Bispecific Epitope CD5 CAR-T Cells for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Presenter: Yuxuan Song¹˒³

Corresponding Author: Jing Pan¹˒²

Affiliations:
¹ Beijing GoBroad Hospital

² Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

³ China Pharmaceutical University

Poster Presentations

Among the 26 poster presentations, key research areas include:

• Novel CAR-T therapies for relapsed/refractory B-ALL, T-ALL/LBL, AML, lymphoma, and multiple myeloma

• Long-term outcomes and optimization strategies for allogeneic hematopoietic stem cell transplantation (allo-HSCT)

• Genomic profiling and clonal evolution in relapsed/refractory multiple myeloma

• Prognostic modeling and risk stratification for CAR-T recipients

• Immune microenvironment characterization and deep immune phenotyping

• Pediatric lymphoma genomics, molecular classification, and prognostic biomarkers

• Real-world studies evaluating CAR-T treatment patterns and outcomes

• Innovative combination approaches integrating targeted therapies, transplantation, and cellular immunotherapy

Scientific exploration knows no boundaries, and clinical innovation begins with patient needs. GoBroad physicians remain committed to advancing high-quality clinical research and translating scientific discoveries into more precise, effective, and accessible treatment options. Through continuous innovation, the team strives to extend survival, improve quality of life, and pursue higher levels of clinical cure for patients with hematologic diseases and cancer.